P. Martin

发表

Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.

Paul D. Martin, E. Lenz, A. Dane, 2003, Clinical therapeutics.

Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.

Paul D. Martin, A. Dane, Paul D Martin, 2003, Clinical therapeutics.

Pharmacokinetic Evaluations of the Co-Administrations of Vandetanib and Metformin, Digoxin, Midazolam, Omeprazole or Ranitidine

Paul D. Martin, E. Lisbon, S. Oliver, 2014, Clinical Pharmacokinetics.

The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive.

Paul D. Martin, D. Schneck, M. Warwick, 2004, British journal of clinical pharmacology.

TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION OF DUODENAL P-GLYCOPROTEIN AND MRP2 IN HEALTHY HUMAN SUBJECTS AFTER CHRONIC TREATMENT WITH RIFAMPIN AND CARBAMAZEPINE.

Paul D. Martin, I. Cascorbi, D. Busch, 2019, Molecular pharmaceutics.

Efficacy and safety of rosuvastatin therapy in children and adolescents with familial hypercholesterolemia: Results from the CHARON study.

Paul D. Martin, G. Francis, D. Gaudet, 2015, Journal of clinical lipidology.

Efficacy and safety of rosuvastatin therapy inchildren and adolescents with familial hypercholesterolemia: Results from the CHARONstudy

Paul D. Martin, G. Francis, D. Gaudet, 2022 .

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models

Paul D. Martin, Mark Cockerill, Paul D. Smith, 2007, Molecular Cancer Therapeutics.

Dysregulation of Mucosal Membrane Transporters and Drug-Metabolizing Enzymes in Ulcerative Colitis.

Paul D. Martin, I. Cascorbi, C. Heidecke, 2019, Journal of pharmaceutical sciences.

Population pharmacokinetics of the MEK inhibitor selumetinib and its active N‐desmethyl metabolite: data from 10 phase I trials

Paul D. Martin, L. Aarons, Diansong Zhou, 2018, British journal of clinical pharmacology.

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

Paul D. Martin, Ali Raza, J. Jarcho, 2004, Clinical pharmacology and therapeutics.

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

Paul D. Martin, K. Lasseter, A. Raza, 2004, Clinical pharmacology and therapeutics.

Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.

Paul D. Martin, Z. Guan, Su Li, 2011, Clinical therapeutics.

Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.

Paul D. Martin, Karen So, E. Lisbon, 2017, Clinical therapeutics.

Metabolism, Excretion, and Pharmacokinetics of Selumetinib, an MEK1/2 inhibitor, in Healthy Adult Male Subjects.

Karen So, G. Mariani, C. Howes, 2016, Clinical therapeutics.

Pharmacokinetics of a Single Oral Dose of the MEK1/2 Inhibitor Selumetinib in Subjects With End‐Stage Renal Disease or Varying Degrees of Hepatic Impairment Compared With Healthy Subjects

Paul D. Martin, Karen So, G. Mariani, 2016, Journal of clinical pharmacology.

Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis

Paul D. Martin, Karen So, G. Mariani, 2017, European Journal of Clinical Pharmacology.

Comparison of normal and reversed-phase solid phase extraction methods for extraction of beta-blockers from plasma using molecularly imprinted polymers.

Paul D. Martin, I. Wilson, G. Jones, 2003, The Analyst.

Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies

Paul D. Martin, S. Oliver, C. Brealey, 2016, Drugs in R&D.

Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.

Paul D. Martin, Karen So, Diansong Zhou, 2016, Clinical therapeutics.

Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies

Paul D. Martin, D. Surry, S. Oliver, 2016, Clinical pharmacology in drug development.

Evaluation of a Molecular-imprinted Polymer for use in the Solid Phase Extraction of Propranolol From Biological Fluids

Ian D. Wilson, Paul D. Martin, Kenneth Jones, 1997 .

Effect of Rosuvastatin on Carotid Intima-Media Thickness in Children With Heterozygous Familial Hypercholesterolemia: The CHARON Study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label)

Paul D. Martin, G. Francis, D. Gaudet, 2017, Circulation.

Characterisation of C18-bonded silicas for solid-phase extraction by solid-state NMR spectroscopy

I. Wilson, K. Albert, R. Brindle, 1994 .

Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia

Paul D. Martin, T. Tzeng, D. Schneck, 2008 .

Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia.

T. Tzeng, D. Schneck, B. Birmingham, 2008, Current medical research and opinion.

The effect of erythromycin on the pharmacokinetics of rosuvastatin

Paul D. Martin, A. Dane, A. Raza, 2003, European Journal of Clinical Pharmacology.

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.

Paul D. Martin, A. Dane, D. Schneck, 2003, Clinical therapeutics.

Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.

Paul D. Martin, D. Schneck, P. Mitchell, 2002, British journal of clinical pharmacology.

Molecular imprints as sorbents for solid phase extraction: potential and applications

Ian D. Wilson, Paul D. Martin, I. Wilson, 1998 .

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.

Paul D. Martin, S. Oliver, M. Hutchison, 2012, Clinical therapeutics.

Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole

Paul D. Martin, S. Oliver, J. Read, 2011, Drugs in R&D.

Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics

Paul D. Martin, K. Lasseter, D. Schneck, 2005, Journal of clinical pharmacology.

Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment

Paul D. Martin, S. Oliver, P. Langmuir, 2010, Clinical pharmacokinetics.

Quantification of the N-desmethyl metabolite of rosuvastatin in human plasma by automated SPE followed by HPLC with tandem MS detection.

M. Warwick, E. Thomas, P. Martin, 2004, Journal of pharmaceutical and biomedical analysis.

Inter-subject variability in intestinal drug solubility.

Paul D. Martin, A. Basit, T. Flanagan, 2015, International journal of pharmaceutics.

Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype

Paul D. Martin, A. Hinks, W. Thomson, 2010, Pharmacogenetics and genomics.

Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure

Paul D. Martin, D. Surry, K. Fenner, 2016, Drug Metabolism and Disposition.

Validation and application of an assay for the determination of mevalonic acid in human plasma by liquid chromatography tandem mass spectrometry.

Paul D. Martin, M. Abrar, P. Martin, 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG‐CoA Reductase Inhibitor

Paul D. Martin, A. Dane, D. Schneck, 2002, Journal of clinical pharmacology.

Methodology for assessing the properties of molecular imprinted polymers for solid phase extraction

I. Wilson, G. Jones, J. Olsen, 1999 .

Application and elution conditions for the selective elution of analytes from molecular imprinted polymers after extraction from aqueous samples: Application to β-blockers

Paul D. Martin, I. Wilson, G. Jones, 2000 .

Clinically Relevant Multidrug Transporters Are Regulated by microRNAs along the Human Intestine.

Paul D. Martin, M. Ostrowski, I. Cascorbi, 2017, Molecular pharmaceutics.

Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.

Paul D. Martin, S. Oliver, T. Marbury, 2015, Clinical therapeutics.

Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies

S. Cheung, M. Gillen, David Han, 2015, European Journal of Clinical Pharmacology.

No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers

Paul D. Martin, J. Kemp, A. Dane, 2002, Journal of clinical pharmacology.

Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects.

Paul D. Martin, A. Dane, A. Raza, 2003, British journal of clinical pharmacology.

Effect of itraconazole on the pharmacokinetics of rosuvastatin

Paul D. Martin, A. Dane, Paul D. Martin, 2003, Clinical pharmacology and therapeutics.

Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials

Paul D. Martin, Karen So, G. Mariani, 2016, European Journal of Clinical Pharmacology.

Estimating the variability in fraction absorbed as a paradigm for informing formulation development in early clinical drug development.

Paul D. Martin, A. Basit, J. Standing, 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.